This page shows the latest NVX-CoV2373 news and features for those working in and with pharma, biotech and healthcare.
New data from a trial conducted in the US and Mexico has showed that Novavax’s COVID-19 vaccine NVX-CoV2373 is 90% effective at preventing COVID-19. ... PREVENT-19 confirms that NVX-CoV2373 offers a reassuring tolerability and safety profile.
Previously, Novavax’s chief executive officer Stanley Erck said that the company was aiming for a US Food and Drug Administration (FDA) emergency approval of its vaccine – NVX-CoV2373 – as early ... Peak capacity for the vaccine is expected in the
Earlier this year, reports emerged that Novavax has encountered issues with sourcing some raw materials used in the manufacturing process for NVX-CoV2373. ... The UK government has already signed an advanced purchase agreement with Novavax for 60 million
GlaxoSmithKline (GSK) has signed an agreement to help make up to 60 million doses of Novavax’s COVID-19 vaccine NVX-CoV2373 in the UK. ... The UK government signed an advanced purchase agreement with Novavax in August 2020 for 60 million doses of
Novavax has revealed final efficacy analysis of its COVID-19 vaccine NVX-CoV2373, after reporting interim results from the UK-based phase 3 trial in January. ... Against the B.1.1.7 strain, first identified in the UK, NVX-CoV2373 was found to be 86.3%,
Novavax has announced that it is to provide 1.1 billion cumulative doses of its COVID-19 vaccine, NVX-CoV2372, to the international vaccines-sharing facility COVAX. ... The doses of NVX-CoV-2373 for COVAX will be manufactured and distributed by Novavax
More from news
Approximately 1 fully matching, plus 15 partially matching documents found.
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...